A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Abstract Text:

Etsuro Orito,Kei Fujiwara,Yasuhito Tanaka,Man-Fung Yuen,Ching-Lung Lai,Takanobu Kato,Fuminaka Sugauchi,Atsunori Kusakabe,Michio Sata,Takeshi Okanoue,Hirofumi Niitsuma,Hiroshi Sakugawa,Izumi Hasegawa,Masashi Mizokami,

BACKGROUND/AIMS: In eastern Asian countries, hepatitis B virus (HBV) genotype Ba (HBV/Ba), HBV/Bj and HBV/C are prevalent. The aim was to investigate the response or resistance to lamivudine therapy among patients with different HBV genotypes. METHODS: Of 67 Japanese and Chinese patients with chronic hepatitis B, 18 patients with HBV/Bj, 15 with HBV/Ba and 34 with HBV/C were selected for a case-control study matched according to gender and age. All the patients were treated with lamivudine for 2 years and evaluated the response or emergence of the YMDD mutation at year 2 during the treatment. HBV genotypes were detected by the restriction fragment length polymorphism. The YMDD mutation was detected by the direct sequencing after amplification by PCR. RESULTS: At year 2 during therapy, 44.8% of the patients showed normalization of ALT and undetectable HBV DNA (favorable response), 35.8% developed the YMDD mutation. There was no significant difference of response to the therapy among the three genotype groups. The emergence of the YMDD mutation was associated with HBV/C. By the multiple logistic regression analysis, however, the significant factor of a favorable response was a higher pretreatment ALT level and negative HBeAg status and the significant factor of the emergence of the YMDD mutation was HBV/C. CONCLUSIONS: Higher pretreatment ALT level, HBeAg status or HBV genotype may affect the response or resistance to lamivudine therapy.

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Publishing Authors By Initials

E Orito,K Fujiwara,Y Tanaka,MF Yuen,CL Lai,T Kato,F Sugauchi,A Kusakabe,M Sata,T Okanoue,H Niitsuma,H Sakugawa,I Hasegawa,M Mizokami,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hepatology research : the official journal of the

VOLUME: 35

Page Numbers: 127-34

Journal Abbreviation:

ISSN: 1386-6346

DAY: 19

MONTH: 04

YEAR: 2006

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711801

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.

AFFILIATION: Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho, Nagoya 467-8601, Japan.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C Related Publications

• A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.
• Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment.
• Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes.
• Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in arctic indigenous populations.
• Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion.
• Development and public release of a comprehensive hepatitis virus database.
• Differences of HBV genotypes and hepatocellular carcinoma in Asian countries.
• Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan.
• Field spread of a diffracted Gaussian beam through a circular aperture.
• Hepatitis B caused by a hepatitis B surface antigen escape mutant.
• Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan.
• Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels.
• Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.
• Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer.
• Pelvic drainage for anterior resection revisited: use of drains in anastomotic leaks.
• Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells.
• Retroposition of the mandible in complete denture wearers.
• Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis.
• Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia.
• Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia.
• Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism.
• Tympanic membrane temperature in a patient with vertigo.
• Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
• When should "i" consider a new hepatitis B virus genotype?
• [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay]
• [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]